Scott John W, van Denderen Bryce J W, Jorgensen Sebastian B, Honeyman Jane E, Steinberg Gregory R, Oakhill Jonathan S, Iseli Tristan J, Koay Ann, Gooley Paul R, Stapleton David, Kemp Bruce E
St. Vincent's Institute and Department of Medicine, University of Melbourne, 41 Victoria Parade, Fitzroy 3065, VIC Australia.
Chem Biol. 2008 Nov 24;15(11):1220-30. doi: 10.1016/j.chembiol.2008.10.005.
The AMP-activated protein kinase (AMPK) is an alphabetagamma heterotrimer that plays a pivotal role in regulating cellular and whole-body metabolism. Activation of AMPK reverses many of the metabolic defects associated with obesity and type 2 diabetes, and therefore AMPK is considered a promising target for drugs to treat these diseases. Recently, the thienopyridone A769662 has been reported to directly activate AMPK by an unexpected mechanism. Here we show that A769662 activates AMPK by a mechanism involving the beta subunit carbohydrate-binding module and residues from the gamma subunit but not the AMP-binding sites. Furthermore, A769662 exclusively activates AMPK heterotrimers containing the beta1 subunit. Our findings highlight the regulatory role played by the beta subunit in modulating AMPK activity and the possibility of developing isoform specific therapeutic activators of this important metabolic regulator.
AMP激活的蛋白激酶(AMPK)是一种αβγ异源三聚体,在调节细胞和全身代谢中起关键作用。AMPK的激活可逆转许多与肥胖和2型糖尿病相关的代谢缺陷,因此AMPK被认为是治疗这些疾病的药物的一个有前景的靶点。最近,噻吩并吡啶A769662已被报道通过一种意想不到的机制直接激活AMPK。在这里,我们表明A769662通过一种涉及β亚基碳水化合物结合模块和γ亚基残基但不涉及AMP结合位点的机制激活AMPK。此外,A769662专门激活含有β1亚基的AMPK异源三聚体。我们的发现突出了β亚基在调节AMPK活性中所起的调节作用,以及开发这种重要代谢调节剂的亚型特异性治疗激活剂的可能性。